

This is a translation of the original Swedish notice. In the event of discrepancies between the Swedish version and this translation, the Swedish version shall prevail.

Press release

Preliminary results for the first quarter of 2011

During the process leading up to the public offer by Medivir AB (publ) ("Medivir") to the shareholders and the holders of listed warrants in BioPhausia AB (publ) ("BioPhausia"), Medivir has been given access to certain preliminary information regarding BioPhausia's financials for the first quarter of 2011.

In order to provide all owners in BioPhausia and the stock market with the corresponding information, the Board of Directors of BioPhausia announces the following:

BioPhausia's net sales for the period January-March, 2011, amounted preliminary to approximately SEK 134m, compared to SEK 112m for the corresponding period in 2010.

Earnings before depreciation and amortisation (EBITDA) for January-March, 2011, amounted preliminary to approximately SEK 31m (including non-recurring income of approximately SEK 2m), compared to SEK 10m for the corresponding period in 2010.

The information regarding the first quarter of 2010 is adjusted for net sales and EBITDA relating to the OTC portfolio of pharmaceuticals that was divested in 2010.

BioPhausia's full interim report for the first quarter of 2011 will be published on May 10, 2011.

Stockholm, April 11, 2011

BioPhausia AB (publ)

The Board of Directors

For further information, please contact:

Maris Hartmanis, CEO BioPhausia AB (publ), tel +46-8-407 64 30

BioPhausia AB (publ) discloses the information provided herein pursuant to the Securities Market Act and the Takeover Rules. The information was submitted for publication on April 11, 2011.